Frontiers in Pharmacology (Sep 2021)

Fibroblast Growth Factor 21 Ameliorates NaV1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes

  • Jiamin Li,
  • Jiamin Li,
  • Yuanshi Li,
  • Yining Liu,
  • Yining Liu,
  • Hang Yu,
  • Hang Yu,
  • Ning Xu,
  • Ning Xu,
  • Di Huang,
  • Di Huang,
  • Yadong Xue,
  • Yadong Xue,
  • Sijia Li,
  • Sijia Li,
  • Haixin Chen,
  • Haixin Chen,
  • Jiali Liu,
  • Jiali Liu,
  • Qingsui Li,
  • Qingsui Li,
  • Yiming Zhao,
  • Yiming Zhao,
  • Ronghao Zhang,
  • Ronghao Zhang,
  • Hongru Xue,
  • Hongru Xue,
  • Yuehang Sun,
  • Yuehang Sun,
  • Ming Li,
  • Ming Li,
  • Pengyu Li,
  • Pengyu Li,
  • Mingbin Liu,
  • Mingbin Liu,
  • Zhen Zhang,
  • Zhen Zhang,
  • Xin Li,
  • Xin Li,
  • Weijie Du,
  • Weijie Du,
  • Ning Wang,
  • Ning Wang,
  • Baofeng Yang,
  • Baofeng Yang

DOI
https://doi.org/10.3389/fphar.2021.715466
Journal volume & issue
Vol. 12

Abstract

Read online

Infarcted myocardium is predisposed to cause lethal ventricular arrhythmias that remain the main cause of death in patients suffering myocardial ischemia. Liver-derived fibroblast growth factor 21 (FGF21) is an endocrine regulator, which exerts metabolic actions by favoring glucose and lipids metabolism. Emerging evidence has shown a beneficial effect of FGF21 on cardiovascular diseases, but the role of FGF21 on ventricular arrhythmias following myocardial infarction (MI) in humans has never been addressed. This study was conducted to investigate the pharmacological effects of FGF21 on cardiomyocytes after MI in humans. Patients with arrhythmia in acute MI and healthy volunteers were enrolled in this study. Serum samples were collected from these subjects on day 1 and days 7–10 after the onset of MI for measuring FGF21 levels using ELISA. Here, we found that the serum level of FGF21 was significantly increased on day 1 after the onset of MI and it returned to normal on days 7–10, relative to the Control samples. In order to clarify the regulation of FGF21 on arrhythmia, two kinds of arrhythmia animal models were established in this study, including ischemic arrhythmia model (MI rat model) and nonischemic arrhythmia model (ouabain-induced guinea pig arrhythmia model). The results showed that the incidence and duration time of ischemic arrhythmias in rhbFGF21-treated MI rats were significantly reduced at different time point after MI compared with normal saline-treated MI rats. Moreover, the onset of the first ventricular arrhythmias was delayed and the numbers of VF and maintenance were attenuated by FGF21 compared to the rhbFGF21-untreated group in the ouabain model. Consistently, in vitro study also demonstrated that FGF21 administration was able to shorten action potential duration (APD) in hydrogen peroxide-treated AC16 cells. Mechanically, FGF21 can ameliorate the electrophysiological function of AC16 cells, which is characterized by rescuing the expression and dysfunction of cardiac sodium current (INa) and inward rectifier potassium (Ik1) in AC16 cells induced by hydrogen peroxide. Moreover, the restorative effect of FGF21 on NaV1.5 and Kir2.1 was eliminated when FGF receptors were inhibited. Collectively, FGF21 has the potential role of ameliorating transmembrane ion channels remodeling through the NaV1.5/Kir2.1 pathway by FGF receptors and thus reducing life-threatening postinfarcted arrhythmias, which provides new strategies for antiarrhythmic therapy in clinics.

Keywords